Growth Stage

Ensuring no one suffers from Peripheral Neuropathy.


Raised to Date: Raised: $596,649

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type


SEC Filing Type

RegCF    Open SEC Filing

Valuation Cap




Rolling Commitments ($USD)

Reporting Date


Days Remaining
% of Min. Goal
% of Max. Goal
Likelihood of Max
Avg. Daily Raise


# of Investors


Create a free account today to gain access to KingsCrowd analytics.
Year Founded



Healthcare & Pharmaceuticals

Tech Sector


San Diego, California

Winsantor is here to make sure that no one suffers from peripheral neuropathy (PN). PN affects 1 in 15 people in the US, and it’s when the nerves die due to disease, injuries, cancer, or genetic diseases. There is currently no treatment -- just drugs that help reduce the pain. Winsantor, however, is currently in trials that show they be on track to reverse the disease, both biologically and functionally. So far, over $30M of non-dilutive funding has driven R&D; they are currently entering Phase 2 of early efficacy studies; and they aim to have their drug approved by 2021 to start helping -- and changing -- the lives of those who are affected.
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
WinSanTor 04/28/2020 StartEngine $75,000,000 $32,651 Convertible Note Funded RegCF
WinSanTor 03/20/2019 Wefunder $70,000,000 $596,649 SAFE Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.

Create your first portfolio

Create your own startup investment portfolio on KingsCrowd.

Track all of your startup investments in one place using our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
WinSanTor on Wefunder
Platform: Wefunder
Security Type: SAFE
Valuation: $70,000,000

Follow company

Follow WinSanTor on Wefunder

Buy WinSanTor's Deal Report

Warning: according to the close date for this deal, WinSanTor may no longer be accepting investments.

WinSanTor Deal Report

Get KingsCrowd’s comprehensive report on WinSanTor including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether WinSanTor is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the WinSanTor deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge Pro